Literature DB >> 24371761

Complex hypereosinophilia arising from post-polycythemia vera myelofibrosis: A case of imatinib-responsiveness.

Ryan D Gentzler1, Alex C Minella1, Brady L Stein1.   

Abstract

The classical myeloproliferative neoplasms (MPNs) feature an overproduction of mature blood elements. Phenotypic conversion, including transformation to myelofibrosis (MF) in those with antecedent ET and PV is a feared complication. Hypereosinophilic syndromes (HESs), especially those with myeloproliferative variants, can display similar features, including organomegaly, marrow fibrosis, clonality, thrombotic tendencies, and acute myeloid leukemia (AML) transformation. However, this group of illnesses is typically clinically and molecularly distinct from the classical MPNs. We report a case of a 59-yr-old woman with complex hypereosinophilia in the setting of post-polycythemic myelofibrosis (post-PVMF), with multi-system end-organ damage characteristic of HES.

Entities:  

Keywords:  Hypereosinophilia syndrome; Imatinib; Myelofibrosis; Myeloproliferative disorder; Polycythemia vera

Year:  2012        PMID: 24371761      PMCID: PMC3787743          DOI: 10.1016/j.lrr.2012.07.001

Source DB:  PubMed          Journal:  Leuk Res Rep        ISSN: 2213-0489


  9 in total

1.  New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia.

Authors:  M C Cox; P Panetta; A Venditti; E Abruzzese; G Del Poeta; M Cantonetti; S Amadori
Journal:  Leuk Res       Date:  2001-04       Impact factor: 3.156

Review 2.  The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1.

Authors:  D Macdonald; A Reiter; N C P Cross
Journal:  Acta Haematol       Date:  2002       Impact factor: 2.195

3.  Hypereosinophilia, JAK2V617F, and Budd-Chiari syndrome: who is responsible for what?

Authors:  Elena Mishchenko; Tamar Tadmor; Elad Schiff; Dina Attias; Aaron Polliack
Journal:  Am J Hematol       Date:  2011-02       Impact factor: 10.047

4.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

Review 5.  Refining the definition of hypereosinophilic syndrome.

Authors:  Hans-Uwe Simon; Marc E Rothenberg; Bruce S Bochner; Peter F Weller; Andrew J Wardlaw; Michael E Wechsler; Lanny J Rosenwasser; Florence Roufosse; Gerald J Gleich; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2010-07       Impact factor: 10.793

Review 6.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2009-08-19       Impact factor: 22.113

7.  Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.

Authors:  Nitin Jain; Jorge Cortes; Alfonso Quintás-Cardama; Taghi Manshouri; Raja Luthra; Guillermo Garcia-Manero; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2008-11-14       Impact factor: 3.156

8.  Hypereosinophilic syndrome associated with polycythemia vera.

Authors:  D Varon; M Wetzler; A Berrebi
Journal:  Arch Intern Med       Date:  1986-07

9.  Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.

Authors:  Bin Li; Guangsen Zhang; Cui Li; Dan He; Xinying Li; Chunfang Zhang; Faqing Tang; Xiyun Deng; Jingchen Lu; Youhong Tang; Ruijuan Li; Zhuchu Chen; Chaojun Duan
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.